Trial Imaging for Cancer

In the era of immunotherapy for cancer treatment, the number of clinical trials for cancer immunotherapeutic agents has been rapidly increasing.

In 2017, the RECIST Working Group released a consensus guideline "iRECIST" for internationally standardized response assessment in multicenter trial.
The iRECIST was developed based on RECIST 1.1, additionally introducing new terminologies and criteria. Accordingly, iRECIST is good for standardized response assessments but also requires cautions to follow.

In this article, we reviewed the overall items of iRECIST, especially focusing on the updated items in iRECIST.